GlaxoSmithKline (GSK) today became the fifth drug manufacturer to loosen or end its 340B contract pharmacy restrictions in Arkansas and [...] …
Month: October 2023
The recent end of a 340B program waiver for hospitals is wrong, hurts hospitals and their patients, and is bound [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Federal courts should allow enforcement of Arkansas’ 340B contract pharmacy law to continue unimpeded, an attorney representing Arkansas told a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The 340B program, enacted in 1992, enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.
In 2010, the 340B program was expanded under the Affordable Care Act, allowing covered entities to contract with an unlimited number of contract pharmacies such as Walgreens to provide 340B discount drugs.
Since July 2020, over 25 unique drug manufactures have imposed restrictions impacting and limiting access to contract pharmacy arrangements. A deeper dive of these 340B restrictions are shared below.
- Claims Data Upload – Most manufacturers have partnered with 340B ESP to require covered entities to upload 340B claims data to access to their contract pharmacy network. Claims upload must follow a standardized format as required by 340B ESP or the manufacturer and uploaded at a recurring cadence to avoid disruption to 340B pricing access. Covered entities who are considering this option should seek counsel from within their organization
The community benefits provided by 340B hospitals surged by $16.5 billion, or 24%, in the latest year analyzed by a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Health Resources and Services Administration (HRSA) confirmed today it is ending a 340B program waiver issued early in the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Genentech, Sanford Health, and Carolina Health Centers’ 340B reform group, 340B Working Table, spent $110,000 on lobbying and gained eight [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
With so many challenges facing health systems today — from 340B contract pharmacy restrictions to drug shortages, labor issues, and ever-rising costs — revenue integrity has become essential to financial stability.
With huge increases in drug expenditures from pre-pandemic levels, health systems must focus on maximizing efficiency, reducing medication costs, and increasing revenue. In this new reality, hospital pharmacies should think and act like a business unit, not just a cost center. Yet many hospitals unknowingly receive reimbursements that fall short of their medication costs, leading to financial strain and plenty of stress and anxiety for hospital and pharmacy administrators.
In healthcare, revenue integrity refers to the comprehensive approach organizations take to ensure accurate billing, appropriate reimbursement, and proper and efficient utilization of resources. For some hospitals, it represents a new way of doing business. If there are gaps and silos in their processes, it’s hard to achieve optimal medication revenue cycle performance.
…
Rep. Mike Johnson (R-La.), the new speaker of the U.S. House, has received campaign donations from multiple 340B stakeholders but [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
GlaxoSmithKline (GSK) recently restricted 340B pricing on Jesduvroq, an anemia treatment, when providers dispense it through contract pharmacies. GSK contractor [...] …